News headlines about Agile Therapeutics (NASDAQ:AGRX) have been trending positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agile Therapeutics earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 47.0261829004423 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several equities analysts have issued reports on AGRX shares. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research note on Friday, December 22nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $8.00 target price on shares of Agile Therapeutics in a research note on Monday, November 20th. HC Wainwright set a $8.00 price target on Agile Therapeutics and gave the stock a “buy” rating in a research note on Friday, December 22nd. William Blair lowered Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, December 26th. Finally, Janney Montgomery Scott lowered Agile Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, December 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $9.20.
Shares of Agile Therapeutics (AGRX) traded up $0.04 during mid-day trading on Friday, hitting $3.69. The stock had a trading volume of 120,917 shares, compared to its average volume of 277,789. Agile Therapeutics has a 1-year low of $1.93 and a 1-year high of $5.60. The stock has a market capitalization of $127.53, a price-to-earnings ratio of -4.01 and a beta of 2.15. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.10 and a quick ratio of 4.10.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thestockobserver.com/2018/02/17/agile-therapeutics-agrx-receives-daily-news-sentiment-rating-of-0-28.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.